Core A is a resource comprised of the individuals who will provide two essential functions in the P01. The first is central organizational, operational, and oversight coordination. The second is the planning, preparation, coordination, and performance of the statistical analyses, including the interpretation of molecular microarrays. The Administrative Core includes Larry Norton, MD, Program Director and Principal Investigator, Agnes Viale, PhD, Coordinator of Molecular Array Technology, Venkatraman Seshan, Biostatistician, Monica Fornier, Liaison to the Breast Cancer Medicine Service, and Edi Brogi, Liaison to Department of Pathology. A major purpose of this core is to promote the integration of the four projects and Core B (Scott Lowe, PhD).
The breadth and complexity of our P01 requires considerable administration to assure optimal performance. This Core A is designed to satisfy that need and thus serve our overall aim: increased knowledge of clinical relevance.
|Chen, Qing; Boire, Adrienne; Jin, Xin et al. (2016) Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533:493-8|
|Kass, Elizabeth M; Lim, Pei Xin; Helgadottir, Hildur R et al. (2016) Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nat Commun 7:13241|
|Gao, Hua; Chakraborty, Goutam; Zhang, Zhanguo et al. (2016) Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. Cell 166:47-62|
|Ebbesen, Saya H; Scaltriti, Maurizio; Bialucha, Carl U et al. (2016) Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A 113:3030-5|
|Malladi, Srinivas; Macalinao, Danilo G; Jin, Xin et al. (2016) Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 165:45-60|
|She, Qing-Bai; Gruvberger-Saal, Sofia K; Maurer, Matthew et al. (2016) Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer 16:587|
|Yang, C; Li, Z; Bhatt, T et al. (2016) Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene :|
|Rodrik-Outmezguine, Vanessa S; Okaniwa, Masanori; Yao, Zhan et al. (2016) Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534:272-6|
|Obenauf, Anna C; Zou, Yilong; Ji, Andrew L et al. (2015) Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520:368-72|
|Okada, Tomoyo; Sinha, Surajit; Esposito, Ilaria et al. (2015) The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. Nat Cell Biol 17:81-94|
Showing the most recent 10 out of 96 publications